Morgan Stanley’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,031,170
| Closed | -$132M | – | 8181 |
|
|
2025
Q2 | $132M | Buy |
1,031,170
+462,471
| +81% | +$48M | 0.01% | 1126 |
|
|
2025
Q1 | $50.3M | Buy |
568,699
+64,356
| +13% | +$6.28M | ﹤0.01% | 1810 |
|
|
2024
Q4 | $44M | Sell |
504,343
-32,019
| -6% | -$2.93M | ﹤0.01% | 1944 |
|
|
2024
Q3 | $49.6M | Buy |
536,362
+115,103
| +27% | +$11.4M | ﹤0.01% | 1826 |
|
|
2024
Q2 | $45.4M | Sell |
421,259
-637,430
| -60% | -$63.8M | ﹤0.01% | 1847 |
|
|
2024
Q1 | $100M | Sell |
1,058,689
-1,277,061
| -55% | -$110M | 0.01% | 1191 |
|
|
2023
Q4 | $215M | Buy |
2,335,750
+1,968,917
| +537% | +$128M | 0.01% | 1106 |
|
|
2023
Q3 | $18.4M | Sell |
366,833
-22,663
| -6% | -$1.21M | ﹤0.01% | 2539 |
|
|
2023
Q2 | $24.6M | Sell |
389,496
-142,831
| -27% | -$7.76M | ﹤0.01% | 2265 |
|
|
2023
Q1 | $23.9M | Buy |
532,327
+66,798
| +14% | +$3.01M | ﹤0.01% | 2221 |
|
|
2022
Q4 | $20.4M | Sell |
465,529
-1,074,179
| -70% | -$51.5M | ﹤0.01% | 2326 |
|
|
2022
Q3 | $101M | Sell |
1,539,708
-121,084
| -7% | -$7.78M | 0.01% | 879 |
|
|
2022
Q2 | $83.9M | Buy |
1,660,792
+1,436,317
| +640% | +$84.1M | 0.01% | 1042 |
|
|
2022
Q1 | $14.3M | Buy |
224,475
+85,298
| +61% | +$6.12M | ﹤0.01% | 2472 |
|
|
2021
Q4 | $14.9M | Buy |
139,177
+4,294
| +3% | +$449K | ﹤0.01% | 2491 |
|
|
2021
Q3 | $13.9M | Sell |
134,883
-400,563
| -75% | -$37.3M | ﹤0.01% | 2521 |
|
|
2021
Q2 | $47.1M | Buy |
535,446
+473,445
| +764% | +$43.4M | 0.01% | 1351 |
|
|
2021
Q1 | $6.03M | Sell |
62,001
-172,240
| -74% | -$17.2M | ﹤0.01% | 3219 |
|
|
2020
Q4 | $26.3M | Buy |
234,241
+166,963
| +248% | +$17.6M | ﹤0.01% | 1562 |
|
|
2020
Q3 | $6.24M | Sell |
67,278
-8,762
| -12% | -$675K | ﹤0.01% | 2499 |
|
|
2020
Q2 | $5.93M | Buy |
76,040
+289
| +0.4% | +$19.5K | ﹤0.01% | 2494 |
|
|
2020
Q1 | $4.43M | Sell |
75,751
-37,733
| -33% | -$2.43M | ﹤0.01% | 2578 |
|
|
2019
Q4 | $9.09M | Buy |
113,484
+66,942
| +144% | +$5.01M | ﹤0.01% | 2528 |
|
|
2019
Q3 | $3.42M | Sell |
46,542
-9,506
| -17% | -$822K | ﹤0.01% | 3290 |
|
|
2019
Q2 | $5.29M | Buy |
56,048
+18,322
| +49% | +$1.51M | ﹤0.01% | 2871 |
|
|
2019
Q1 | $3.02M | Sell |
37,726
-203,087
| -84% | -$15M | ﹤0.01% | 3213 |
|
|
2018
Q4 | $13M | Buy |
240,813
+124,331
| +107% | +$7.56M | ﹤0.01% | 1849 |
|
|
2018
Q3 | $9.09M | Sell |
116,482
-256,940
| -69% | -$17.9M | ﹤0.01% | 2511 |
|
|
2018
Q2 | $23.7M | Buy |
373,422
+186,125
| +99% | +$14.8M | 0.01% | 1481 |
|
|
2018
Q1 | $17.2M | Sell |
187,297
-156,658
| -46% | -$13.5M | ﹤0.01% | 1807 |
|
|
2017
Q4 | $25.9M | Buy |
343,955
+283,972
| +473% | +$20M | 0.01% | 1443 |
|
|
2017
Q3 | $4.18M | Buy |
59,983
+12,003
| +25% | +$641K | ﹤0.01% | 3162 |
|
|
2017
Q2 | $2.43M | Sell |
47,980
-41,688
| -46% | -$1.77M | ﹤0.01% | 3628 |
|
|
2017
Q1 | $3.59M | Sell |
89,668
-4,825
| -5% | -$173K | ﹤0.01% | 3226 |
|
|
2016
Q4 | $2.65M | Buy |
94,493
+85,122
| +908% | +$2.57M | ﹤0.01% | 3666 |
|
|
2016
Q3 | $279K | Sell |
9,371
-21,995
| -70% | -$546K | ﹤0.01% | 4846 |
|
|
2016
Q2 | $635K | Buy |
31,366
+2,478
| +9% | +$45K | ﹤0.01% | 4292 |
|
|
2016
Q1 | $521K | Sell |
28,888
-1,809
| -6% | -$31.4K | ﹤0.01% | 4412 |
|
|
2015
Q4 | $809K | Buy |
30,697
+3,189
| +12% | +$71.8K | ﹤0.01% | 4202 |
|
|
2015
Q3 | $587K | Buy |
27,508
+26,083
| +1,830% | +$721K | ﹤0.01% | 4501 |
|
|
2015
Q2 | $38K | Buy |
+1,425
| New | +$40.7K | ﹤0.01% | 5944 |
|
Other funds holding BPMC
IA
HNB
Morgan Stanley's BPMC Position: Q3 2025 in Review
Morgan Stanley sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,031,170 shares — an estimated $132M sold.
Morgan Stanley first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $215M in Q4 2023. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Morgan Stanley reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 1,031,170 Blueprint Medicines shares in Q3 2025, an estimated $132M.
- Morgan Stanley first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- Morgan Stanley's Blueprint Medicines position peaked at $215M in Q4 2023.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.